Gilead to Fly High with Kite Pharma Acquisition for $11.9B – Yahoo Finance
San Francisco Chronicle |
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
Yahoo Finance We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The most advanced therapy candidate … 'Game-changer' cancer treatment is focus of Gilead's $12 billion cell therapy deal Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma Closes Gilead's $11.9 billion purchase of a groundbreaking cancer therapy could drag it into a new debate on prices |
